(RTTNews) - Jasper Therapeutics, Inc. (JSPR), a clinical-stage biotechnology company, announced on Friday the pricing of an underwritten public offering to raise $29.6 million in gross proceeds.
The firm has priced an underwritten public offering of about 11.67 million common shares with accompanying common warrants at $2.43 per share and warrant.
The company also offers pre-funded warrants to purchase up to 675,000 common shares and accompanying common warrants, at $2.43 less the $0.0001 exercise price per pre-funded warrant.
The offering is expected to close on or about September 22, subject to closing conditions.
The pre-funded warrants will be immediately exercisable, while common warrants will be exercisable starting six months from issuance at $2.92 per share and will remain exercisable for four years.
The company plans to use the net proceeds to advance preclinical and clinical development of briquilimab in mast-cell driven diseases and for general corporate purposes, including capital expenditures, working capital, and administrative expenses.
On Thursday, Jasper Therapeutic closed trading, 4.25% lesser at $2.4800 on the Nasdaq.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
